Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 2011. The report discloses a notifiable change in shareholding regarding OctoPlus N.V., a pharmaceuticals product and drug delivery company based in the Netherlands.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on a specific equity holding change.
Material Changes
Following a private placement offering by OctoPlus N.V. on October 26, 2011, GSK's interest in the company decreased. GSK's holding, managed through its wholly owned US subsidiary S.R. One, Limited, now stands at 4,345,062 ordinary shares, representing 9.7% of OctoPlus's total issued share capital (44,778,974 shares outstanding). This reduction caused the holding to fall below the 10% threshold required for disclosure under the Dutch Financial Supervision Act.
Outlook, Risks, and Management Commentary
Management commentary is limited to the notification of the shareholding decrease. GSK is required to notify the Netherlands Authority for the Financial Markets (AFM) of this change on November 18, 2011. No specific guidance, risks, or unusual items regarding GSK's core operations are detailed in this filing.
Key Facts for Investor Verification
- GSK's stake in OctoPlus N.V. has dropped to 9.7% following a private placement.
- The holding is maintained by S.R. One, Limited, a GSK subsidiary.
- The disclosure was triggered by the stake falling below the 10% regulatory threshold in the Netherlands.
- No financial performance data for GSK is included in this specific report.